Key Takeaways MRK will report Q4 results on Feb. 3, with investors watching the performance of key non-oncology drugs.MRK is leaning on Capvaxive and Winrevair after strong launches, with $480M and $976M sales in 9M 2025.Animal Health growth and early Enflonsia sales are likely to support MRK's top-line growth beyond oncology.As Merck (MRK) is gearing up to report its fourth-quarter and full-year 2025 results on Feb. 3, investors' focus is likely to be on the sales performance of its blockbuster cancer drug ...

Core Insights - Merck's stock surged by 41% over the last six months, driven by modest revenue growth, significant profit increases, and heightened investor confidence [2][4]. Financial Performance - Revenue increased by 0.5%, while net margin rose by 8.6%, contributing to the stock's performance [4]. - The P/E multiple saw a significant increase of 27%, indicating improved investor sentiment [4]. Key Developments - Strong Q3 2025 earnings results included a 10% growth for Keytruda, exceeding expectations and prompting an increase in FY25 guidance [9]. - The FDA approved Keytruda QLEX (SC) for solid tumors, enhancing treatment convenience [9]. - Positive Phase 3 results for Enlicitide, an oral PCSK9 inhibitor, were announced, indicating potential for future growth [9]. - Merck raised its future revenue projections to $70 billion by the mid-2030s, reflecting optimism about new growth drivers [9]. - Encouraging long-term data for a personalized cancer vaccine with Keytruda in melanoma was reported, further supporting the growth narrative [9].

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-e ...

We recently published 10 Big Names Stumbling Hard. Revolution Medicines Inc. (NASDAQ:RVMD) was one of the worst performers on Monday. Revolution Medicines fell sharply on Monday, losing 16.91 percent to close at $97.78 apiece, as investors unloaded portfolios following news that pharmaceutical giant Merck had cancelled ongoing negotiations for its proposed acquisition of the company. According to a report by the Wall Street Journal, Merck decided to terminate talks after failing to agree on a valuation. ...

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the “Neutral” zone on Monday.U.S. stocks settled higher on Monday, with the Dow Jones index gaining more than 300 points during the session ahead of a big week of major earnings reports and interest rate decision from the Federal Reserve. Meanwhile, stocks recorded losses last week, with the 30-stock Dow losing 0.5% and the S&P 500 falling about 0.4%.Revolution Medicines Inc (NASDAQ:RVMD) sh ...

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the “Neutral” zone on Monday.U.S. stocks settled higher on Monday, with the Dow Jones index gaining more than 300 points during the session ahead of a big week of major earnings reports and interest rate decision from the Federal Reserve. Meanwhile, stocks recorded losses last week, with the 30-stock Dow losing 0.5% and the S&P 500 falling about 0.4%.Revolution Medicines Inc (NASDAQ:RVMD) sh ...

It doesn't look like the company will end up in the arms of an acquirer soon, after all.Monday was generally a good day for the stock market; nevertheless, some titles landed in negative territory. One that plunged well into the red was clinical-stage biotech Revolution Medicines (RVMD 16.76%), which took a nearly 17% hit to its share price after a media report published over the weekend. Buyout bluesOn Sunday, The Wall Street Journal wrote that Merck was no longer in discussions with Revolution regarding a ...

Welcome back to Market on Close. I'm Sam Bardis live from the floor of the New York Stock Exchange. Shares of Revolution Medicines are rallying to an all-time high earlier this month, but the stock is plummeting today.That comes after a Wall Street Journal report that is today's overlooked stock. And with more on this story, I'm joined by George Silla, senior markets correspondent. So, this has got a bit of an M&A Monday flavor to it.George, just talk us through it. >> Yeah, well, I think this is interestin ...

Market Overview - The trading day is concluding with a modest rally in major indices, with the Dow Jones Industrial Average up 300 points (0.6%), the S&P 500 up 35 points (0.5%), and the Nasdaq up 0.4% [7][8]. - The upcoming week is anticipated to be significant for the market, particularly with earnings reports from major tech companies like Meta, Microsoft, Apple, and Tesla [3][6]. Earnings Expectations - Analysts expect a broadening of the earnings picture, indicating that not only big tech names will be in focus but also other companies that may show meaningful earnings and revenue growth [6][7]. - The sentiment around the Federal Reserve's upcoming meeting and Fed Chair Jerome Powell's comments will also play a crucial role in market momentum [5][6]. Sector Performance - Communication services led the sector performance, driven by companies like Alphabet and Meta, while consumer discretionary and consumer staples sectors saw declines [9][10]. - Rare earth companies experienced significant movement, particularly USA Rare Earths, which rose nearly 8% following a non-binding agreement with the U.S. Commerce Department for $1.6 billion in funding to boost domestic production [11][13]. Company-Specific News - Nvidia announced an additional $2 billion investment in a cloud computing firm, contributing to a 5.7% increase in its stock price, which is up over 40% year-to-date [14]. - GameStop shares rose approximately 4.5% after Michael Barr expressed confidence in the company's future and his recent purchases of shares [15]. - Booz Allen Hamilton's shares fell over 8% after the U.S. Treasury canceled $21 million in contracts due to data protection failures [17]. - The Trade Desk's stock declined more than 7% following the termination of its CFO, Alex Kail [18]. - Revolution Medicines saw a significant drop of 17% after reports that Merck ended acquisition talks, raising concerns about valuation discipline [20]. Economic Impact - A notable decline in bookings (35%) at a Vermont ski resort was reported, attributed to strained U.S.-Canada relations affecting Canadian customers [28][30]. - The economic ramifications of these relations are highlighted as a microcosm of broader macroeconomic issues impacting both sides of the border [31].

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...